Fever-Tree has performed ahead of expectations as the mixer brand gained momentum in the second half of its financial year, especially in the US.
Revenues in the year to 31 December increased 2% to £372.7m and adjusted EBITDA for the year will be marginally ahead of market forecasts.
Sales in the US in FY25 jumped by 3% to £131.9m – and by 6% when adjusting for currency movements – as Fever-Tree integrated into the Molson Coors national distribution network.
The UK registered a 2% decline in sales to £108.4m on the back of softness in the on-trade, but trading “notably improved” in the second half, driven by a robust off-trade performance with increasing momentum across the group’s portfolio outside of tonics, particularly in premium soft drinks.
Revenues in Europe had a 2% bump to £94.7m and rose 17% in the rest of the world to £37.7m.
“We made excellent progress in 2025,” CEO Tim Warrillow said. “Our partnership with Molson Coors in the US is progressing well, and the momentum behind the brand is especially encouraging, giving us confidence in the growing opportunity in our largest market as execution moves beyond the transition phase.
“Across all our markets, we are continuing to build momentum as we broaden Fever-Tree beyond tonic, positioning the brand as not only the premium mixer but also premium soft drink of choice. We are uniquely positioned to unlock the growth opportunities afforded by the consumer trends towards moderation, premiumisation and longer, lighter serves.
“With exciting marketing campaigns and a strong innovation pipeline, delivered by our passionate team, I am confident we will drive strong growth in 2026 and beyond.”
No comments yet